Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108425 | 0.85 | CSNK2A1 (0.40) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10108328 | 0.85 | CSNK2A1 (0.40) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10108424 | 0.85 | CSNK2A1 (0.40) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10108323 | 0.80 | CSNK2A1 (0.43) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10108330 | 0.72 | CYP1A2 (0.31) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10108427 | 0.69 | MAOA (0.38) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL28794242 | 0.66 | LMNA (0.43) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10102699 | 0.62 | LMNA (0.44) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL13190704 | 0.61 | CSNK2A1 (0.41) | CSNK2A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10108563 | 0.61 | PSMB8 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CSNK2A1 323/4885ALDH1A1 3257/4885PDE4A 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.